Pharmaceutical majors Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) have experienced a significant increase in their market value on Thursday, driven by the potential of their weight-loss drugs, GLP-1s, to address the global obesity epidemic. This optimism has propelled sales forecasts into the hundreds of billions. However, this same optimism has negatively impacted companies that have traditionally profited from treating obesity-related complications.
Among those adversely affected are insulin-pump manufacturers Insulet (NASDAQ:PODD) and Tandem Diabetes Care (NASDAQ:TNDM). Their stocks have seen a drastic reduction, with Insulet's shares plummeting by 40% and Tandem Diabetes Care witnessing a 50% drop in its stock value. DexCom, a leading producer of glucose monitors, has also suffered a 16% drop in its share value.
Similarly, companies involved in sleep apnea treatment have been hit hard. ResMed, a prominent producer of Continuous Positive Airway Pressure (CPAP) machines, has seen its stock decline by 30%. Inspire Medical Systems (NYSE:INSP), a firm offering another type of sleep apnea device, has experienced an 18% fall in its share price.
Additionally, Madrigal Pharmaceuticals (NASDAQ:MDGL), known for its work in liver-disease drug development, has witnessed a significant decrease in its market value with shares down by 40%.
In contrast to these companies' downturns, Eli Lilly and Novo Nordisk continue to prosper due to the potential of their GLP-1s to combat obesity. The shift in market dynamics illustrates the significant impact of the growing optimism surrounding obesity treatment on various sectors within the healthcare industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.